However, in a randomized phase III double-blind clinical trial, tivantinib did not improve OS time in patients with Met-high advanced HCC treated with sorafenib compared with placebo (Rimassa et al., 2018) (NCT01755767)
These agents target multiple hormone pathways involved in appetite regulation, insulin secretion, energy expenditure, and hepatic metabolism
J.WidelM
Evans-Hoeker EA, Eisenberg E, Diamond MP, et al
Hims had said last week that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month
When clinically appropriate and permitted by applicable law, your provider may recommend medications prepared by a state-licensed compounding pharmacy as part of your individualized treatment plan